Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sonnet BioTherapeutics Holdings, Inc. SONN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Sonnet BioTherapeutics Holdings, Inc. (SONN) is a Biotechnology company in the Healthcare sector, currently trading at $1.26. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $1M, +1707.9%/yr average growth. Net income is $16M (loss), growing at -6.5%/yr. Net profit margin is -1611.3% (negative). Gross margin is 0% (-73.4 pp trend).

Balance sheet: total debt is $46,573 against $11M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 3.5 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $15M.

Analyst outlook: 4 / 4 analysts rate SONN as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

SONN SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SONN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
SONN: +1707.9%/yr revenue is, -6.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SONN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 3.5 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate SONN as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
SONN: Net profit margin is -1611.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.08-19.3
Volume10.43M
Avg Volume (30D)1.11M
Market Cap$8.43M
Beta (1Y)1.47
Share Statistics
EPS (TTM)-3.95
Shares Outstanding$4.08M
IPO Date2006-10-31
Employees13
CEORaghu Rao
Financial Highlights & Ratios
Revenue (TTM)$1M
EBITDA$-15.84M
Net Income$-16.11M
Operating Income$-15.84M
Total Cash$5.12M
Total Debt$46.57K
Net Debt$-5.07M
Total Assets$14.88M
Price / Earnings (P/E)-0.3
Price / Sales (P/S)8.43
Analyst Forecast
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS83548R4020

Price Chart

Track all markets on TradingView
SONN
Sonnet BioTherapeutics Holdings, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.08 52WK RANGE 19.30

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 YS
YS
YS Biopharma Co., Ltd.
$1.02
+9.68%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.19
-0.76%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.64
+5.18%
 KRBP
KRBP
Kiromic BioPharma, Inc.
$0.08
-2.33%
 NAVB
NAVB
Navidea Biopharmaceuticals, Inc.
$0.00
0.00%
 EFTR
EFTR
eFFECTOR Therapeutics, Inc.
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message